Poliovirus Patents (Class 424/217.1)
  • Patent number: 11298317
    Abstract: The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: April 12, 2022
    Assignee: Deuteria Beverages, LLC
    Inventors: Anthony W. Czarnik, Jeffrey A. McKinney
  • Patent number: 10633662
    Abstract: Compositions and methods are provided for modulating adeno-associated virus (AAV) infection. For example, compositions and methods are provided for enhancing permissiveness of a target cell to AAV infection (e.g., by increasing levels of AAVR (KIAA0319L) in the cell), for reducing permissiveness of a target cell to AAV infection (e.g., by reducing levels of AAVR in the cell), and for nucleic acid delivery (e.g., by (i) increasing permissiveness of a target cell to AAV infection, e.g., by increasing the amount of AAVR in the cell; and (ii) contacting the target cell with an AAV particle that includes a nucleic acid of interest). Also provided are screening methods and kits for practicing the methods of the disclosure.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: April 28, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Oregon Health & Science University
    Inventors: Sirika Pillay, Jan Carette, Michael Stewart Chapman, Nancy Meyer, Andreas Puschnik, Omar Davulcu
  • Patent number: 10603352
    Abstract: The present disclosure provides a drug formulation for hepalatide, comprising hepalatide and a buffer salt, and containing or not containing an osmotic regulator and/or an excipient.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 31, 2020
    Assignee: Shanghai HEP Pharmaceutical Co., Ltd.
    Inventor: Hongli Liu
  • Patent number: 9642907
    Abstract: The present invention relates to a composition comprising a viral antigen, a first protein and a second protein. Optionally, the composition also comprises three different disaccharaides, or, optionally, the composition comprises a primary sugar and at least one, preferably two secondary sugars. The present invention also relates to the use of a viral antigen, a first protein and a second protein for the manufacture of a composition, preferably a vaccine. The present invention furthermore relates to a method of treatment or prevention of virus associates diseases in humans. Moreover, the present invention relates to a method of adapting a virus to a suitable cell-line. The invention is also useful for the production of virus suspensions suitable for making stable, live/inactivated, monovalent and/or polyvalent, liquid/lyophilized rotavirus vaccine compositions for oral and/or nasal or any other suitable route of administration in human.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: May 9, 2017
    Assignee: Bharat Biotech International Limited
    Inventors: Krishna Murthy Ella, Victor Jerusha Augustus Harshavardhan Gutla, Krishna Mohan Vadrevu, Smita Suneel Singhania
  • Patent number: 9402892
    Abstract: The invention provides an attenuated polio virus having a 5? non-coding region consisting of the 5? non-coding region of Sabin 3, modified so that it does not have a base pair mismatch in stem (a) or (b) of domain V, wherein seven or eight of the base pairs in stems (a) and (b) are U-A or A-U base pairs; and a capsid protein from the Sabin 1, Mahoney, MEF or Saukett strain.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: August 2, 2016
    Assignee: The Secretary of State for Health
    Inventor: Andrew MacAdam
  • Patent number: 9023319
    Abstract: Provided herein are methods for immunizing children under six months of age by administering to the child a pharmaceutical composition comprising at least one antigen derived from an influenza virus.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: May 5, 2015
    Assignee: Sanofi Pasteur Inc.
    Inventor: Michael Decker
  • Publication number: 20150056250
    Abstract: The present invention is directed to methods for administering antigenic material to a patient as a vaccine against an infection comprising providing both an antigenic material specific to the desired immunological response desired plus an adjuvant comprised of a peptide of a sequence derived from the sequence of pneumococcal surface adhesin A protein (PsaA). Preferably the peptide comprises a sequences derived from one or more sequences of PsaA that contain the epitope regions or contiguous amino acids of SEQ ID NOs 1 or 2. The invention is also directed to vaccine compositions containing adjuvant of the invention and also adjuvant compositions of the invention.
    Type: Application
    Filed: May 13, 2013
    Publication date: February 26, 2015
    Inventor: Subhash KAPRE
  • Patent number: 8945582
    Abstract: The standard dose of polio vaccines contains 40 D-antigen units of inactivated poliovirus type 1 (Mahoney), 8 D-antigen units of inactivated poliovirus type 2 (MEF-1), and 32 D-antigens units of inactivated poliovirus type 3 (Saukett). The present invention teaches that reduced doses of inactivated poliovirus can maintain adequate or improved level of protection against polio.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 3, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Herve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
  • Publication number: 20150030629
    Abstract: The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt. Preferably the amino acid is glutamate, the polyol is sorbitol and optionally also mannitol and the metal salt is a magnesium salt. The solution is dried by vacuum drying or by lyophilization. The methods are particularly useful for preparing dried formulations of viruses such as poliovirus or respiratory syncytial virus to be used for vaccination. The invention also relates to dried formulations prepared in accordance with the methods of the invention and to their use as medicaments, e.g. as vaccines.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 29, 2015
    Applicants: en Sport
    Inventors: Heleen Kraan, Jean-Pierre Amorij
  • Publication number: 20150030563
    Abstract: The present invention relates to the treatment, alleviation, prevention or reduction in the incidence of symptoms, diseases or conditions resulting from or associated with enteroviruses, more particularly the enteroviral infections they cause.
    Type: Application
    Filed: August 5, 2014
    Publication date: January 29, 2015
    Inventors: Johan NEYTS, Armando De Palma, Hendrik Jan Thibaut, Pieter Leyssen, Simon Tucker
  • Patent number: 8921101
    Abstract: A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5? non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155 tumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: December 30, 2014
    Assignee: The Research Foundation of The State University of New York
    Inventors: Eckard Wimmer, Jeronimo Cello, Aniko Paul, Hidemi Toyoda, Jiang Yin
  • Publication number: 20140242113
    Abstract: This document provides methods and materials involved in making and using liquid vaccine preparations for oral administration. For example, methods and materials for making and using liquid vaccine preparations for oral administration that include a lyophilized or dried vaccine component (e.g., a lyophilized pathogenic agent such as a lyophilized rotavirus preparation) and a liquid edible oil composition (e.g., a liquid edible oil composition containing one or more medium chain triglycerides) are provided. In some cases, liquid vaccine preparations that include a buffer component (e.g., CaCO3) are provided.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 28, 2014
    Inventor: Leonard P. Ruiz, JR.
  • Publication number: 20140227320
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 14, 2014
    Inventors: Shawn P. Iadonato, Kristin Bedard, Myra Wang Imanaka, Kerry W. Fowler
  • Publication number: 20140219954
    Abstract: The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium stearate.
    Type: Application
    Filed: March 17, 2014
    Publication date: August 7, 2014
    Inventor: Rudi Mueller-Walz
  • Publication number: 20140112952
    Abstract: The invention provides an attenuated poliovirus which does not have a base pair mismatch in stem (a) or (b) of domain V of the 5? non-coding region of its genome, wherein at least seven of the base pairs in stems (a) and (b) are U-A or A-U base pairs.
    Type: Application
    Filed: October 14, 2013
    Publication date: April 24, 2014
    Applicant: THE SECRETARY OF STATE FOR HEALTH
    Inventor: Andrew MacAdam
  • Publication number: 20130344108
    Abstract: The invention provides an attenuated polio virus having a 5? non-coding region consisting of the 5? non-coding region of Sabin 3, modified so that it does not have a base pair mismatch in stem (a) or (b) of domain V, wherein seven or eight of the base pairs in stems (a) and (b) are U-A or A-U base pairs; and a capsid protein from the Sabin 1, Mahoney, MEF or Saukett strain.
    Type: Application
    Filed: December 29, 2011
    Publication date: December 26, 2013
    Applicant: THE SECRETARY OF STATE FOR HEALTH
    Inventor: Andrew MacAdam
  • Publication number: 20130273106
    Abstract: Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventor: John A. Lewis
  • Patent number: 8557252
    Abstract: The invention provides an attenuated poliovirus which does not have a base pair mismatch in stem (a) or (b) of domain V of the 5? non-coding region of its genome, wherein at least seven of the base pairs in stems (a) and (b) are U-A or A-U base pairs.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: October 15, 2013
    Assignee: The Secretary of State for Health
    Inventor: Andrew MacAdam
  • Patent number: 8551527
    Abstract: The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: October 8, 2013
    Assignee: Sanofi Pasteur S.A.
    Inventors: Pierre Chouvenc, Alain Francon
  • Patent number: 8546123
    Abstract: Provided is a process for the production of poliovirus, comprising the steps of: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: October 1, 2013
    Assignee: Crucell Holland B.V.
    Inventor: John Alfred Lewis
  • Publication number: 20130052224
    Abstract: Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.
    Type: Application
    Filed: October 25, 2012
    Publication date: February 28, 2013
    Applicant: Crucell Holland B.V.
    Inventor: Crucell Holland B.V.
  • Publication number: 20130045229
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 21, 2013
    Applicant: KINETA, INC.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Publication number: 20130039945
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 14, 2013
    Applicant: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Publication number: 20130039944
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 14, 2013
    Applicant: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Publication number: 20120294830
    Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
    Type: Application
    Filed: July 6, 2012
    Publication date: November 22, 2012
    Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
  • Publication number: 20120244182
    Abstract: The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: September 27, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventor: Nicholas M. VALIANTE
  • Publication number: 20120171292
    Abstract: The disclosure relates to immunizing agents and devices.
    Type: Application
    Filed: January 3, 2012
    Publication date: July 5, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael J. Sailor, Stephen M. Hedrick, Lou Gu, Laura Ruff, Zhengtao Qin
  • Patent number: 8182805
    Abstract: The present invention relates to prevention and treatment of allergic sensitization and diseases associated therewith by treatment with an enterovirus vaccine, wherein the enterovirus does not contain an exogenous nucleic acid sequence that is integrated into the viral genome and that encodes an allergen that induces said allergic sensitization.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: May 22, 2012
    Assignee: Vactech Oy
    Inventors: Hanna Viskari, Mikael Knip, Tapio Seiskari, Heikki Hyöty, Laura Kummola, Anita Kondrashova
  • Patent number: 8173411
    Abstract: The present invention relates to a method of drying biological and other labile samples so that they can be preserved as a highly viscous liquid. The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilizing agent, subjecting the preservation sample to such temperature and pressure conditions that the preservation sample looses solvent by evaporation without freezing or bubbling to form a foam and removing solvent until the preservation sample dries to form a highly viscous liquid. The stabilizing solution comprises a glass forming polyol and a second component which decreases the flow rate of the highly viscous liquid formed by the method.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: May 8, 2012
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: Yves Mayeresse
  • Publication number: 20120045430
    Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.
    Type: Application
    Filed: August 15, 2011
    Publication date: February 23, 2012
    Inventors: Dan Luo, Yougen Li
  • Publication number: 20110293723
    Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: May 26, 2011
    Publication date: December 1, 2011
    Applicant: Selecta Biosciences, Inc.
    Inventors: Robert L. Bratzler, Grayson B. Lipford, Lloyd Johnston, Charles Zepp
  • Patent number: 8066983
    Abstract: A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5? non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155 tumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: November 29, 2011
    Assignee: The Research Foundation of State University of New York
    Inventors: Eckard Wimmer, Jeronimo Cello, Aniko Paul, Hidemi Toyoda, Jiang Yin
  • Publication number: 20110268764
    Abstract: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.
    Type: Application
    Filed: May 3, 2011
    Publication date: November 3, 2011
    Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
    Inventors: Monika Sachet, Michael Bergmann, Thomas Muster, Andrej Egorov
  • Publication number: 20110206683
    Abstract: The invention relates to a preservation composition, a formulation comprising a preservation mixture of glutamate, a saccharide, and a polymer. Said preservation mixture is advantageously used for the preservation of a biological compound.
    Type: Application
    Filed: October 22, 2009
    Publication date: August 25, 2011
    Applicant: DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS
    Inventors: Cornelis Wilhelmus Van Ingen, Chen Shu-hui Tan
  • Patent number: 7972592
    Abstract: Live virus vaccines comprise attenuated viruses, while other vaccines comprise killed viruses or parts thereof. It has now been found that the immune response induced by oral poliovirus vaccine (OPV), which is a live vaccine, is cross-reactive with non-polio enteroviruses. OPV is therefore useful in the prevention of non-polio enterovirus diseases, especially Type 1 diabetes mellitus (IDDM). OPV is also useful in combination with killed/subunit non-polio enterovirus vaccines, whereby it prevents harmful side-effects of the killed/subunit vaccine by shifting the immune response from a harmful Th2-type response to a Th1 type response.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: July 5, 2011
    Inventors: Heikki Hyöty, Mikael Knip
  • Publication number: 20110159038
    Abstract: The present invention relates to a method of drying biological and other labile samples so that they can be preserved as a highly viscous liquid. The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilizing agent, subjecting the preservation sample to such temperature and pressure conditions that the preservation sample loses solvent by evaporation without freezing or bubbling to form a foam and removing solvent until the preservation sample dries to form a highly viscous liquid.
    Type: Application
    Filed: March 11, 2011
    Publication date: June 30, 2011
    Inventor: Yves MAYERESSE
  • Publication number: 20110135679
    Abstract: The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a pharmaceutically acceptable excipient, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.
    Type: Application
    Filed: December 7, 2008
    Publication date: June 9, 2011
    Applicant: NOVARTIS AG
    Inventors: Padma Malyala, Derek O'Hagan, Manmohan Singh
  • Publication number: 20110110979
    Abstract: The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.
    Type: Application
    Filed: April 1, 2009
    Publication date: May 12, 2011
    Applicant: Universite De Lausanne
    Inventor: Denise Nardelli Haefliger
  • Publication number: 20110027317
    Abstract: Provided is a process for the production of poliovirus, comprising the steps of: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.
    Type: Application
    Filed: July 16, 2010
    Publication date: February 3, 2011
    Inventor: John Alfred Lewis
  • Publication number: 20110020392
    Abstract: The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as RA, Tremors/Parkinson's Disease, and MS, and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from RA, MS, Tremors/Parkinson's Disease, and prostrate cancer realized immediate beneficial results with no side effects.
    Type: Application
    Filed: October 14, 2008
    Publication date: January 27, 2011
    Applicant: Salubrious Pharmaceutical, LLC
    Inventor: George Nelson
  • Publication number: 20100285135
    Abstract: Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such compositions and kits supplying such compositions.
    Type: Application
    Filed: December 1, 2006
    Publication date: November 11, 2010
    Applicant: NOVARTIS AG
    Inventors: Janet R. Wendorf, Manmohan Singh, Derek T. O'Hagan
  • Patent number: 7758868
    Abstract: The invention encompasses compositions and methods relating to viral polymerases having one or more substitutions of different amino acids at conserved regions of the polymerase yields enzymes with varying rates and fidelity of replication. A universally applicable, polymerase-mechanism-based strategy for production of attenuated viruses and anti-viral vaccines is disclosed.
    Type: Grant
    Filed: December 24, 2007
    Date of Patent: July 20, 2010
    Assignee: The Penn State Research Foundation
    Inventors: Craig E. Cameron, Christian Castro, Jamie J. Arnold
  • Publication number: 20100158945
    Abstract: The invention provides an attenuated poliovirus which does not have a base pair mismatch in stem (a) or (b) of domain V of the 5? non-coding region of its genome, wherein at least seven of the base pairs in stems (a) and (b) are U-A or A-U base pairs.
    Type: Application
    Filed: August 10, 2007
    Publication date: June 24, 2010
    Inventor: Andrew MacAdam
  • Publication number: 20100136043
    Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.
    Type: Application
    Filed: October 21, 2009
    Publication date: June 3, 2010
    Applicant: AUSTIN RESEARCH INSTITUTE
    Inventor: Magdalena Plebanski
  • Publication number: 20100129400
    Abstract: The invention encompasses compositions and methods relating to viral polymerases having one or more substitutions of different amino acids at conserved regions of the polymerase yields enzymes with varying rates and fidelity of replication. A universally applicable, polymerase-mechanism-based strategy for production of attenuated viruses and anti-viral vaccines is disclosed. Attenuated viruses serve as vaccines and were shown to provide protection against poliovirus challenge in vivo.
    Type: Application
    Filed: January 12, 2010
    Publication date: May 27, 2010
    Applicant: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Craig Cameron, Jamie Arnold, Avery August
  • Publication number: 20100112078
    Abstract: The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wherein surprisingly the nanoparticle induces cellular response and the microparticle induces humoral response. The invention further provides a method of inducing cellular and/or humoral immune response.
    Type: Application
    Filed: September 25, 2009
    Publication date: May 6, 2010
    Applicant: NATIONAL INSTITUTE OF IMMUNOLOGY
    Inventors: Amulya K. Panda, Kanchan Vibhu
  • Publication number: 20100055129
    Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Application
    Filed: August 28, 2009
    Publication date: March 4, 2010
    Applicant: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Publication number: 20090280142
    Abstract: A method of detecting osteoporosis in a mammalian is disclosed herein which includes: a) obtaining a sample of a bone related tissue or cells; and b) measuring the concentration of at least a marker which is either bacteria, bacteria produced factors, or HSPs. The method may further include comparing the concentration with concentrations from the same individual over a period of time or against a standard concentration. The marker may be a bacteria, a chaperone molecule, or a bacteria produced. Also provided herein is a method of treating or preventing osteoporosis caused by a bone disease which includes administering to a mammalian subject a therapeutically effective amount of a formulation which is either an HSP antigenic formulation or a bacterial antigenic formulation. The osteoporosis can be caused by a bone disease induced by bone infectious agents such as viruses, bacteria, fungi, protozoa and parasites.
    Type: Application
    Filed: May 18, 2009
    Publication date: November 12, 2009
    Applicant: DEPUY MITEK, INC.
    Inventors: Kai-Uwe Lewandrowski, Debra J. Trantolo
  • Publication number: 20090214537
    Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.
    Type: Application
    Filed: May 12, 2006
    Publication date: August 27, 2009
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Marco Soriani, Isabella Santi
  • Patent number: 7579144
    Abstract: Methods are provided for detecting enteroviral antigens in the stomach of patients having symptoms consistent with chronic fatigue syndrome (CFS). The presence of enteroviral viral antigens in the stomach of these patients is then correlated with the patients' symptoms to establish a diagnosis of CFS.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: August 25, 2009
    Assignee: EV Med Research
    Inventor: John K. S. Chia